Gilead Sciences Inc
GILD:NASDAQ
| Last | Change / % Change | Dividend Yield | Volume | Avg Volume (10 day) |
| 56.36 | 0.00 0.00% | 0.00% | 0 | 14.4M |
Recent News Headlines for Gilead Sciences Inc
- Gilead Announces Response Data from Phase 2 Study of Idelalisib for Previously Untreated Chronic Lymphocytic Leukemia
-- Regimen Achieves 97 Percent Overall Response Rate with Estimated Progression-Free Survival at 24 Months of 93 Percent -- -- Results from Study 101-08 and Other Idelalisib Clinical Studies to Be Presented at American Society of Clinical Oncology Annual Meeting --
- Gilead Sciences to Present at the Bank of America Merrill Lynch 2013 Health Care Conference on Wednesday, May 15
Webcast Available Through Gilead Corporate Website FOSTER CITY, Calif.--(BUSINESS WIRE)--May 14, 2013-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that its corporate presentation will be webcast from the Bank of America Merrill Lynch 2013 Health Care Conference in Las Vegas.
- Critical Alerts For Gilead, Schlumberger, Charles Schwab, Trulia, and Staples Released By InvestorsObserver
CHICAGO, May 6, 2013 InvestorsObserver issues critical PriceWatch Alerts for V, GILD, SLB, SCHW, TRLA, and SPLS. (Photo: http://photos.prnewswire.com/prnh/20120712/CG39046) To see what our analysts have discovered about these stocks read the InvestorsObserver's PriceWatch Alerts at http://www.investorsobserver.com/pr/5320131 (Note: You may have to copy this link into your browser then press the [ENTER] key.)
- Gilead Sciences Announces First Quarter 2013 Financial Results
- Product Sales of $2.39 billion, Up 8 percent over First Quarter 2012 - - Total Revenues of $2.53 billion, Up 11 percent over First Quarter 2012 - - Reiterates Full Year 2013 Guidance -
- Gilead Sciences Announces First Quarter 2013 -2-
In February, Gilead announced: -- Topline results from the Phase 3 FISSION study, evaluating therapy with either a 12-week course of sofosbuvir plus RBV or standard of care with